Congenitally uncorrected transposition of the great arteries with coarctation

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

No FDA or trial events recorded yet for Congenitally uncorrected transposition of the great arteries with coarctation.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

0

Total programs

No financial assistance programs currently listed for Congenitally uncorrected transposition of the great arteries with coarctation.
Check the disease page for updates →

Approved Treatments

1 FDA-approved

MEKINIST

(trametinib)Orphan drugstandard

Novartis Pharmaceuticals Corp.

12.1 Mechanism of Action Trametinib is a reversible inhibitor of mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 activation ...

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for Congenitally uncorrected transposition of the great arteries with coarctation.
Search all trials →
Search clinical trials for Congenitally uncorrected transposition of the great arteries with coarctation

Recent News & Research

No recent news articles indexed yet for Congenitally uncorrected transposition of the great arteries with coarctation.
Search PubMed for Congenitally uncorrected transposition of the great arteries with coarctation

Browse all Congenitally uncorrected transposition of the great arteries with coarctation news →

Specialist Network

No specialists currently listed for Congenitally uncorrected transposition of the great arteries with coarctation.

View all Congenitally uncorrected transposition of the great arteries with coarctation specialists →

Quick Actions